Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458235 · ClinicalTrials.gov registry record · Phase 2
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02458235 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 17 participants.
The verdict
NCT02458235, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young adult patients with hematologic malignancies who have undergone hematopoietic stem cell transplantation (HSCT).
Interventions
- DRUG azacitidine
- BIOLOGICAL donor lymphocyte infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02458235
The ClinicalTrials.gov registry entry for NCT02458235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azacitidine is the first listed.
NCT02458235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02458235 about?
NCT02458235 is a clinical study titled "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation". The goal of this study is to determine whether post-transplant consolidation with azacitidine combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the prevention of relapse in pediatric and young adult patients with hematologic malignancies who have undergone hematopoie...
What is the current status of trial NCT02458235?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-06-02. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT02458235?
The interventions under investigation include: azacitidine (DRUG), donor lymphocyte infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02458235?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.